{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:12:30Z","timestamp":1772453550831,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heterozygous mutations of the hydroxymethylbilane synthase gene can lead to acute intermittent porphyria, with episodic abdominal pain and neuropsychiatric symptoms. The heme precursors 5-aminolevulinic acid and porphobilinogen accumulate due to enzyme deficiency. Case reports of biallelic pathogenic hydroxymethylbilane synthase gene variants are very rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case report presents a severely affected boy with biallelic pathogenic hydroxymethylbilane synthase gene variants and includes literature overview of other case reports and experimental data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>At the age of 2 years, a Caucasian boy with pathologic psychomotor development was diagnosed with biallelic pathogenic hydroxymethylbilane synthase gene variants. As in previous case reports, he did not exhibit symptoms of acute intermittent porphyria, but progressive cystic leukoencephalopathy and neurological decay. In his urine, 5-aminolevulinic acid and porphobilinogen were markedly elevated, but in cerebrospinal fluid just porphobilinogen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Literature review<\/jats:title>\n                    <jats:p>Data of human and animal studies indicate that neurologic symptoms of acute intermittent porphyria are caused by 5-aminolevulinic acid, which episodically accumulates from hepatic origin. Here, as long-term treatment, the inhibition of hepatic heme synthesis with the small interfering RNA givosiran has proven to be effective. In case of biallelic pathogenic hydroxymethylbilane synthase gene variants, the heme precursors 5-aminolevulinic acid or porphobilinogen originating from the liver or central nervous system could be causative, and absolute heme deficiency in the central nervous system is another hypothesis. However, parenterally administered heme, which is effective in acute intermittent porphyria, does not reach the central nervous system. In one case of biallelic pathogenic hydroxymethylbilane synthase gene variants, a liver transplantation did not lead to long-term benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For differential diagnosis of cystic leukoencephalopathy, biallelic pathogenic hydroxymethylbilane synthase gene variants should be considered. Its pathogenesis probably differentiates from acute intermittent porphyria. To date, there is no promising therapeutic approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-05879-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:06:18Z","timestamp":1771877178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biallelic pathogenic hydroxymethylbilane synthase gene variants of a neurodegenerative disorder with progressive cystic leukoencephalopathy: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6513-5174","authenticated-orcid":false,"given":"Gabriel","family":"Schacht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Elbracht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Elisabeth","family":"Minder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Stoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Lausberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"H\u00e4usler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"1","key":"5879_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2007-1007139","volume":"18","author":"UA Meyer","year":"1998","unstructured":"Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998;18(1):43\u201352.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"5879_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2007-1007136","volume":"18","author":"B Grandchamp","year":"1998","unstructured":"Grandchamp B. Acute intermittent porphyria. Semin Liver Dis. 1998;18(1):17\u201324.","journal-title":"Semin Liver Dis"},{"issue":"7","key":"5879_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11910-022-01205-7","volume":"22","author":"K Wylie","year":"2022","unstructured":"Wylie K, Testai FD. Neurological manifestations of acute porphyrias. Curr Neurol Neurosci Rep. 2022;22(7):355\u201362.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"12","key":"5879_CR4","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1016\/j.clinph.2011.07.036","volume":"122","author":"CS Lin","year":"2011","unstructured":"Lin CS, Lee MJ, Park SB, Kiernan MC. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin Neurophysiol. 2011;122(12):2336\u201344.","journal-title":"Clin Neurophysiol"},{"issue":"1-2","key":"5879_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molbrainres.2005.02.007","volume":"137","author":"A Sengupta","year":"2005","unstructured":"Sengupta A, Hon T, Zhang L. Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Brain Res Mol Brain Res. 2005;137(1\u20132):23\u201330.","journal-title":"Brain Res Mol Brain Res"},{"key":"5879_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122205","author":"A Ricci","year":"2021","unstructured":"Ricci A, Di Pierro E, Marcacci M, Ventura P. Mechanisms of neuronal damage in acute hepatic porphyrias. Diagnostics. 2021. https:\/\/doi.org\/10.3390\/diagnostics11122205.","journal-title":"Diagnostics"},{"issue":"7","key":"5879_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Givosiran: a review in acute hepatic porphyria. Drugs. 2021;81(7):841\u20138.","journal-title":"Drugs"},{"key":"5879_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.715523","volume":"15","author":"PVS de Souza","year":"2021","unstructured":"de Souza PVS, Badia BdML, Farias IB, Pinto WBVR, Oliveira ASB. Acute hepatic porphyria: pathophysiological basis of neuromuscular manifestations. Front Neurosci. 2021;15: 715523.","journal-title":"Front Neurosci"},{"issue":"3","key":"5879_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1590\/S0004-282X1954000300005","volume":"79","author":"PVS de Souza","year":"2021","unstructured":"de Souza PVS, Badia BdML, Farias IB, Gon\u00e7alves EA, Pinto WBVR, Oliveira ASB. Acute hepatic porphyrias for the neurologist: current concepts and perspectives. Arq Neuropsiquiatr. 2021;79(3):249\u201358.","journal-title":"Arq Neuropsiquiatr"},{"issue":"5","key":"5879_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","volume":"36","author":"G Elder","year":"2013","unstructured":"Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849\u201357.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"5879_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.1365-2796.1997.00189.x","volume":"242","author":"Y Nordmann","year":"1997","unstructured":"Nordmann Y, Puy H, Da Silva V, Simonin S, Robreau AM, Bonaiti C, et\u00a0al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med. 1997;242(3):213\u20137.","journal-title":"J Intern Med"},{"issue":"11","key":"5879_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/humu.23067","volume":"37","author":"B Chen","year":"2016","unstructured":"Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, et\u00a0al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37(11):1215\u201322.","journal-title":"Hum Mutat"},{"issue":"7","key":"5879_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/hmg\/ddy030","volume":"27","author":"H Lenglet","year":"2018","unstructured":"Lenglet H, Schmitt C, Grange T, Manceau H, Karboul N, Bouchet-Crivat F, et\u00a0al. From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. Hum Mol Genet. 2018;27(7):1164\u201373.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5879_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1031-7","volume":"14","author":"M Barreda-Sanchez","year":"2019","unstructured":"Barreda-Sanchez M, Buendia-Martinez J, Glover-Lopez G, Carazo-Diaz C, Ballesta-Martinez MJ, Lopez-Gonzalez V, et\u00a0al. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor. Orphanet J Rare Dis. 2019;14(1): 59.","journal-title":"Orphanet J Rare Dis"},{"key":"5879_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020675","author":"HJ Bustad","year":"2021","unstructured":"Bustad HJ, Kallio JP, Vorland M, Fiorentino V, Sandberg S, Schmitt C, et\u00a0al. Acute intermittent porphyria: an overview of therapy developments and future perspectives focusing on stabilisation of HMBS and proteostasis regulators. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020675.","journal-title":"Int J Mol Sci"},{"issue":"6390","key":"5879_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/359033a0","volume":"359","author":"GV Louie","year":"1992","unstructured":"Louie GV, Brownlie PD, Lambert R, Cooper JB, Blundell TL, Wood SP, et\u00a0al. Structure of porphobilinogen deaminase reveals a flexible multidomain polymerase with a single catalytic site. Nature. 1992;359(6390):33\u20139.","journal-title":"Nature"},{"issue":"11","key":"5879_CR17","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/archneur.61.11.1764","volume":"61","author":"C Solis","year":"2004","unstructured":"Solis C, Martinez-Bermejo A, Naidich TP, Kaufmann WE, Astrin KH, Bishop DF, et\u00a0al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol. 2004;61(11):1764\u201370.","journal-title":"Arch Neurol"},{"issue":"10","key":"5879_CR18","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/ajmg.a.62377","volume":"185","author":"CA Stutterd","year":"2021","unstructured":"Stutterd CA, Kidd A, Florkowski C, Janus E, Fanjul M, Raizis A, et\u00a0al. Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations. Am J Med Genet A. 2021;185(10):2941\u201350.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"5879_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF00207051","volume":"89","author":"DH Llewellyn","year":"1992","unstructured":"Llewellyn DH, Smyth SJ, Elder GH, Hutchesson AC, Rattenbury JM, Smith MF. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet. 1992;89(1):97\u20138.","journal-title":"Hum Genet"},{"issue":"3","key":"5879_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2019.05.010","volume":"128","author":"N Dixon","year":"2019","unstructured":"Dixon N, Li T, Marion B, Faust D, Dozier S, Molina A, et\u00a0al. Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias. Mol Genet Metab. 2019;128(3):228\u201335.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"5879_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1212\/WNL.0000000000003129","volume":"87","author":"SH Kevelam","year":"2016","unstructured":"Kevelam SH, Neeleman RA, Waisfisz Q, Friesema EC, Langendonk JG, van der Knaap MS. Acute intermittent porphyria-related leukoencephalopathy. Neurology. 2016;87(12):1258\u201365.","journal-title":"Neurology"},{"key":"5879_CR22","first-page":"731","volume":"32","author":"VH De Villeneuve","year":"1964","unstructured":"De Villeneuve VH, Wadman SK, Van De Heuvel JM. A child with a special form of porphyria. Maandschr Kindergeneeskd. 1964;32:731\u201342.","journal-title":"Maandschr Kindergeneeskd"},{"issue":"5","key":"5879_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/BF01799566","volume":"13","author":"GJ Beukeveld","year":"1990","unstructured":"Beukeveld GJ, Wolthers BG, Nordmann Y, Deybach JC, Grandchamp B, Wadman SK. A retrospective study of a patient with homozygous form of acute intermittent porphyria. J Inherit Metab Dis. 1990;13(5):673\u201383.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"5879_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/BF01799567","volume":"13","author":"C Picat","year":"1990","unstructured":"Picat C, Delfau MH, de Rooij FW, Beukeveld GJ, Wolthers BG, Wadman SK, et\u00a0al. Identification of the mutations in the parents of a patient with a putative compound heterozygosity for acute intermittent porphyria. J Inherit Metab Dis. 1990;13(5):684\u20136.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"5879_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/B:BOLI.0000016613.75677.05","volume":"27","author":"J Hessels","year":"2004","unstructured":"Hessels J, Voortman G, van der Wagen A, van der Elzen C, Scheffer H, Zuijderhoudt FM. Homozygous acute intermittent porphyria in a 7-year-old boy with massive excretions of porphyrins and porphyrin precursors. J Inherit Metab Dis. 2004;27(1):19\u201327.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"5879_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2014.11.029","volume":"62","author":"X Schneider-Yin","year":"2015","unstructured":"Schneider-Yin X, van Tuyll van Serooskerken AM, Siegesmund M, Went P, Barman-Aksozen J, Bladergroen RS, et\u00a0al. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. J Hepatol. 2015;62(3):734\u20138.","journal-title":"J Hepatol"},{"issue":"4","key":"5879_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jhep.2022.05.018","volume":"77","author":"L Molina","year":"2022","unstructured":"Molina L, Zhu J, Trepo E, Bayard Q, Amaddeo G, Consortium G, et\u00a0al. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. J Hepatol. 2022;77(4):1038\u201346.","journal-title":"J Hepatol"},{"issue":"4","key":"5879_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2796.1996.21847000.x","volume":"240","author":"C Andersson","year":"1996","unstructured":"Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med. 1996;240(4):195\u2013201.","journal-title":"J Intern Med"},{"issue":"5","key":"5879_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/hep.31460","volume":"73","author":"B Saberi","year":"2021","unstructured":"Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, et\u00a0al. Hepatocellular carcinoma in acute hepatic porphyrias: results from the longitudinal study of the U.S. Porphyrias Consortium. Hepatology. 2021;73(5):1736\u201346.","journal-title":"Hepatology"},{"issue":"1","key":"5879_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainres.2006.03.103","volume":"1093","author":"A Adhikari","year":"2006","unstructured":"Adhikari A, Penatti CA, Resende RR, Ulrich H, Britto LR, Bechara EJ. 5-aminolevulinate and 4, 5-dioxovalerate ions decrease GABA(A) receptor density in neuronal cells, synaptosomes and rat brain. Brain Res. 2006;1093(1):95\u2013104.","journal-title":"Brain Res"},{"issue":"12","key":"5879_CR31","first-page":"458","volume":"57","author":"DM Becker","year":"1980","unstructured":"Becker DM, Cayanis E, Kramer S. The effect of delta-aminolevulinic acid on the synthesis and metabolism of GABA in rabbit brain homogenates. S Afr Med J. 1980;57(12):458\u201360.","journal-title":"S Afr Med J"},{"issue":"6","key":"5879_CR32","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/j.1471-4159.1979.tb02291.x","volume":"32","author":"MJ Brennan","year":"1979","unstructured":"Brennan MJ, Cantrill RC. The effect of delta-aminolaevulinic acid on the uptake and efflux of [3H]GABA in rat brain synaptosomes. J Neurochem. 1979;32(6):1781\u20136.","journal-title":"J Neurochem"},{"issue":"2","key":"5879_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/0014-4886(83)90234-0","volume":"79","author":"L Terr","year":"1983","unstructured":"Terr L, Weiner LP. An autoradiographic study of delta-aminolevulinic acid uptake by mouse brain. Exp Neurol. 1983;79(2):564\u20138.","journal-title":"Exp Neurol"},{"issue":"6","key":"5879_CR34","first-page":"219","volume":"52","author":"VA Percy","year":"1977","unstructured":"Percy VA, Shanley BC. Prophyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria. S Afr Med J. 1977;52(6):219\u201322.","journal-title":"S Afr Med J"},{"issue":"11","key":"5879_CR35","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/hmg\/ddz003","volume":"28","author":"M Yasuda","year":"2019","unstructured":"Yasuda M, Gan L, Chen B, Yu C, Zhang J, Gama-Sosa MA, et\u00a0al. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria. Hum Mol Genet. 2019;28(11):1755\u201367.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5879_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00910-z","volume":"8","author":"S Berger","year":"2020","unstructured":"Berger S, Stattmann M, Cicvaric A, Monje FJ, Coiro P, Hotka M, et\u00a0al. Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria. Acta Neuropathol Commun. 2020;8(1): 38.","journal-title":"Acta Neuropathol Commun"},{"issue":"17","key":"5879_CR37","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1093\/hmg\/ddv222","volume":"24","author":"C Homedan","year":"2015","unstructured":"Homedan C, Schmitt C, Laafi J, Gueguen N, Desquiret-Dumas V, Lenglet H, et\u00a0al. Mitochondrial energetic defects in muscle and brain of a Hmbs-\/- mouse model of acute intermittent porphyria. Hum Mol Genet. 2015;24(17):5015\u201323.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5879_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ng0296-195","volume":"12","author":"RL Lindberg","year":"1996","unstructured":"Lindberg RL, Porcher C, Grandchamp B, Ledermann B, Burki K, Brandner S, et\u00a0al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet. 1996;12(2):195\u20139.","journal-title":"Nat Genet"},{"issue":"4","key":"5879_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/mgme.2000.2975","volume":"69","author":"AV Corrigall","year":"2000","unstructured":"Corrigall AV, Hift RJ, Davids LM, Hancock V, Meissner D, Kirsch RE, et\u00a0al. Homozygous variegate porphyria in South Africa: genotypic analysis in two cases. Mol Genet Metab. 2000;69(4):323\u201330.","journal-title":"Mol Genet Metab"},{"issue":"8381","key":"5879_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0140-6736(84)92298-0","volume":"1","author":"V Korda","year":"1984","unstructured":"Korda V, Deybach JC, Martasek P, Zeman J, da Silva V, Nordmann Y, et\u00a0al. Homozygous variegate porphyria. Lancet. 1984;1(8381):851.","journal-title":"Lancet"},{"issue":"2","key":"5879_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2133.2005.06978.x","volume":"154","author":"P Poblete-Gutierrez","year":"2006","unstructured":"Poblete-Gutierrez P, Wolff C, Farias R, Frank J. A Chilean boy with severe photosensitivity and finger shortening: the first case of homozygous variegate porphyria in South America. Br J Dermatol. 2006;154(2):368\u201371.","journal-title":"Br J Dermatol"},{"issue":"816","key":"5879_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/pgmj.69.816.781","volume":"69","author":"RJ Hift","year":"1993","unstructured":"Hift RJ, Meissner PN, Todd G, Kirby P, Bilsland D, Collins P, et\u00a0al. Homozygous variegate porphyria: an evolving clinical syndrome. Postgrad Med J. 1993;69(816):781\u20136.","journal-title":"Postgrad Med J"},{"issue":"7","key":"5879_CR43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ced.12071","volume":"38","author":"VA Pinder","year":"2013","unstructured":"Pinder VA, Holden ST, Deshpande C, Siddiqui A, Mellerio JE, Wraige E, et\u00a0al. Homozygous variegate porphyria presenting with developmental and language delay in childhood. Clin Exp Dermatol. 2013;38(7):737\u201340.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"5879_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0021-9258(18)65809-0","volume":"219","author":"D Mauzerall","year":"1956","unstructured":"Mauzerall D, Granick S. The occurrence and determination of delta-amino-levulinic acid and porphobilinogen in urine. J Biol Chem. 1956;219(1):435\u201346.","journal-title":"J Biol Chem"},{"key":"5879_CR45","first-page":"379","volume":"29","author":"Armbruster","year":"1983","unstructured":"Armbruster. Auftrennung und Quantifizierung der Porphyrine mit Hilfe der Hochleistungs-Fl\u00fcssigkeits-Chromatographie. \u00c4rztl Lab. 1983;29:379\u201384.","journal-title":"\u00c4rztl Lab."},{"issue":"2","key":"5879_CR46","first-page":"111","volume":"16","author":"M Doss","year":"1978","unstructured":"Doss M, von Tiepermann R. [Uroporphyrinogen synthase in erythrocytes in acute intermittent porphyria: new pathobiochemical aspects (author transl)]. J Clin Chem. 1978;16(2):111\u20138.","journal-title":"J Clin Chem"},{"issue":"4","key":"5879_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1373\/clinchem.2005.058198","volume":"52","author":"Y Floderus","year":"2006","unstructured":"Floderus Y, Sardh E, Moller C, Andersson C, Rejkjaer L, Andersson DE, et\u00a0al. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem. 2006;52(4):701\u20137.","journal-title":"Clin Chem"},{"issue":"10","key":"5879_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/NEN.0b013e3181f2eafa","volume":"69","author":"M Bugiani","year":"2010","unstructured":"Bugiani M, Boor I, Powers JM, Scheper GC, van der Knaap MS. Leukoencephalopathy with vanishing white matter: a review. J Neuropathol Exp Neurol. 2010;69(10):987\u201396.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"5879_CR49","first-page":"23","volume":"59","author":"SJ Perlman","year":"2012","unstructured":"Perlman SJ, Mar S. Leukodystrophies. Adv Pediatr. 2012;59(1):23\u201354.","journal-title":"Adv Pediatr"},{"issue":"1","key":"5879_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14737175.2020.1699060","volume":"20","author":"MR Ashrafi","year":"2020","unstructured":"Ashrafi MR, Amanat M, Garshasbi M, Kameli R, Nilipour Y, Heidari M, Rezaei Z, Tavasoli AR. An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Rev Neurother. 2020;20(1):65\u201378.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"5879_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10545-008-0778-0","volume":"30","author":"F Sedel","year":"2007","unstructured":"Sedel F, Tourbah A, Fontaine B, Lubetzki C, Baumann N, Saudubray JM, Lyon-Caen O. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis. 2007;30(3):295\u2013305.","journal-title":"J Inherit Metab Dis"},{"key":"5879_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1384678","volume":"15","author":"P Sgobbi","year":"2024","unstructured":"Sgobbi P, Serrano PL, Badia BdML, Farias IB, Oliveira Z, Barbosa AS, Pereira CA, Moreira VF, Pinto IFN, Oliveira ASB, Pinto WBVR. Neurofilament light chain as a biomarker for acute hepatic porphyrias. Front Neurol. 2024;15: 1384678.","journal-title":"Front Neurol"},{"issue":"1","key":"5879_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000152455.38510.af","volume":"84","author":"M Fraunberg","year":"2005","unstructured":"Fraunberg M, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltimore). 2005;84(1):35\u201347.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"5879_CR54","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/003655100300054891","volume":"60","author":"C Andersson","year":"2000","unstructured":"Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest. 2000;60(7):643\u20138.","journal-title":"Scand J Clin Lab Invest"},{"issue":"Pt 3","key":"5879_CR55","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1042\/bst0310731","volume":"31","author":"PM Shoolingin-Jordan","year":"2003","unstructured":"Shoolingin-Jordan PM, Al-Dbass A, McNeill LA, Sarwar M, Butler D. Human porphobilinogen deaminase mutations in the investigation of the mechanism of dipyrromethane cofactor assembly and tetrapyrrole formation. Biochem Soc Trans. 2003;31(Pt 3):731\u20135.","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"5879_CR56","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20130045","volume":"33","author":"HJ Bustad","year":"2013","unstructured":"Bustad HJ, Vorland M, Ronneseth E, Sandberg S, Martinez A, Toska K. Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. Biosci Rep. 2013;33(4): e00056.","journal-title":"Biosci Rep"},{"issue":"1","key":"5879_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/BJ20082077","volume":"420","author":"R Gill","year":"2009","unstructured":"Gill R, Kolstoe SE, Mohammed F, Al D-Bass A, Mosely JE, Sarwar M, et\u00a0al. Structure of human porphobilinogen deaminase at 2.8 A: the molecular basis of acute intermittent porphyria. Biochem J. 2009;420(1):17\u201325.","journal-title":"Biochem J"},{"issue":"8","key":"5879_CR58","first-page":"861","volume":"48","author":"A Edixhoven-Bosdijk","year":"2002","unstructured":"Edixhoven-Bosdijk A, de Rooij FW, de Baar-Heesakkers E, Wilson JH. Residual activity of human porphobilinogen deaminase with R167Q or R167W mutations: an explanation for survival of homozygous and compound heterozygous acute intermittent porphyrics. Cell Mol Biol. 2002;48(8):861\u20136.","journal-title":"Cell Mol Biol"},{"issue":"4","key":"5879_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1034\/j.1399-0004.2002.620406.x","volume":"62","author":"Y Floderus","year":"2002","unstructured":"Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet. 2002;62(4):288\u201397.","journal-title":"Clin Genet"},{"issue":"2","key":"5879_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bcmd.2003.12.003","volume":"32","author":"L von Brasch","year":"2004","unstructured":"von Brasch L, Zang C, Haverkamp T, Schlechte H, Heckers H, Petrides PE. Molecular analysis of acute intermittent porphyria: mutation screening in 20 patients in Germany reveals 11 novel mutations. Blood Cells Mol Dis. 2004;32(2):309\u201314.","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"5879_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/1098-1004(200010)16:4<373::AID-HUMU14>3.0.CO;2-A","volume":"16","author":"A De Siervi","year":"2000","unstructured":"De Siervi A, Weiss Cadiz DE, Parera VE, del Batlle AM, Rossetti MV. Identification and characterization of two novel mutations that produce acute intermittent porphyria: a 3-base deletion (841\u2013843delGGA) and a missense mutation (T35M). Hum Mutat. 2000;16(4):373.","journal-title":"Hum Mutat"},{"issue":"1","key":"5879_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000074909","volume":"51","author":"I Bylesjo","year":"2004","unstructured":"Bylesjo I, Brekke OL, Prytz J, Skjeflo T, Salvesen R. Brain magnetic resonance imaging white-matter lesions and cerebrospinal fluid findings in patients with acute intermittent porphyria. Eur Neurol. 2004;51(1):1\u20135.","journal-title":"Eur Neurol"},{"issue":"39","key":"5879_CR63","first-page":"2776","volume":"91","author":"J Yuan","year":"2011","unstructured":"Yuan J, Peng B, You H, Zhang W. Clinical and neuroimaging features of central nervous system impairments in acute intermittent porphyria. Zhonghua Yi Xue Za Zhi. 2011;91(39):2776\u20138.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"10","key":"5879_CR64","first-page":"SD01","volume":"10","author":"S Mohanlal","year":"2016","unstructured":"Mohanlal S, Ghildiyal RG, Kondekar A, Wade P, Sinha R. A commonly missed well known entity- Acute intermittent porphyria: a case report. J Clin Diagn Res. 2016;10(10):SD01-SD2.","journal-title":"J Clin Diagn Res"},{"issue":"8","key":"5879_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7326\/0003-4819-154-8-201104190-00015","volume":"154","author":"JK Dowman","year":"2011","unstructured":"Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome PN. Liver transplantation from donors with acute intermittent porphyria. Ann Intern Med. 2011;154(8):571\u20132.","journal-title":"Ann Intern Med"},{"issue":"9410","key":"5879_CR66","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(04)15646-8","volume":"363","author":"ZF Soonawalla","year":"2004","unstructured":"Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, et\u00a0al. Liver transplantation as a cure for acute intermittent porphyria. Lancet. 2004;363(9410):705\u20136.","journal-title":"Lancet"},{"issue":"4","key":"5879_CR67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1053\/j.gastro.2022.10.029","volume":"164","author":"B Wang","year":"2023","unstructured":"Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023;164(4):1051\u201362.","journal-title":"Gastroenterology"},{"issue":"5","key":"5879_CR68","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00415-023-11586-5","volume":"270","author":"E Pischik","year":"2023","unstructured":"Pischik E, Baumann K, Karpenko A, Kauppinen R. Pathogenesis of acute encephalopathy in acute hepatic porphyria. J Neurol. 2023;270(5):2613\u201330.","journal-title":"J Neurol"},{"issue":"5","key":"5879_CR69","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/j.1471-4159.2007.04905.x","volume":"103","author":"Y Hu","year":"2007","unstructured":"Hu Y, Shen H, Keep RF, Smith DE. Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem. 2007;103(5):2058\u201365.","journal-title":"J Neurochem"},{"issue":"12","key":"5879_CR70","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/j.1460-9568.2005.04471.x","volume":"22","author":"L Wang","year":"2005","unstructured":"Wang L, Yan D, Gu Y, Sun LG, Ruan DY. Effects of extracellular delta-aminolaevulinic acid on sodium currents in acutely isolated rat hippocampal CA1 neurons. Eur J Neurosci. 2005;22(12):3122\u20138.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"5879_CR71","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/0014-4886(78)90287-X","volume":"62","author":"CA Pierach","year":"1978","unstructured":"Pierach CA, Edwards PS. Neurotoxicity of delta-aminolevulinic acid and porphobilinogen. Exp Neurol. 1978;62(3):810\u20134.","journal-title":"Exp Neurol"},{"issue":"4","key":"5879_CR72","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2005.10.011","volume":"87","author":"R Akagi","year":"2006","unstructured":"Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S. delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab. 2006;87(4):329\u201336.","journal-title":"Mol Genet Metab"},{"issue":"14","key":"5879_CR73","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/BF01487615","volume":"61","author":"M Doss","year":"1983","unstructured":"Doss M, Tiepermann RV, Schneider J. Porphobilinogen-synthase (delta-aminolevulinic acid dehydratase) deficiency in bone marrow cells of two patients with porphobilinogen-synthase defect acute porphyria. Klin Wochenschr. 1983;61(14):699\u2013702.","journal-title":"Klin Wochenschr"},{"issue":"1","key":"5879_CR74","first-page":"5","volume":"25","author":"S Thunell","year":"1987","unstructured":"Thunell S, Holmberg L, Lundgren J. Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J Clin Chem Clin Biochem. 1987;25(1):5\u201314.","journal-title":"J Clin Chem Clin Biochem"},{"issue":"4","key":"5879_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1023\/B:BOLI.0000037341.21975.9d","volume":"27","author":"MO Doss","year":"2004","unstructured":"Doss MO, Stauch T, Gross U, Renz M, Akagi R, Doss-Frank M, et\u00a0al. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis. 2004;27(4):529\u201336.","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"5879_CR76","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/clinchem\/44.9.1892","volume":"44","author":"U Gross","year":"1998","unstructured":"Gross U, Sassa S, Jacob K, Deybach JC, Nordmann Y, Frank M, et\u00a0al. 5-Aminolevulinic acid dehydratase deficiency porphyria: a twenty-year clinical and biochemical follow-up. Clin Chem. 1998;44(9):1892\u20136.","journal-title":"Clin Chem"},{"issue":"1","key":"5879_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00063-022-00978-6","volume":"118","author":"F Sayk","year":"2023","unstructured":"Sayk F, Grasshoff L. [Acute hepatic porphyrias]. Med Klin Intensivmed Notfmed. 2023;118(1):21\u20139.","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"3","key":"5879_CR78","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.neuroimage.2010.10.017","volume":"54","author":"M Haris","year":"2011","unstructured":"Haris M, Cai K, Singh A, Hariharan H, Reddy R. In vivo mapping of brain myo-inositol. Neuroimage. 2011;54(3):2079\u201385.","journal-title":"Neuroimage"},{"issue":"3-5","key":"5879_CR79","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000111347","volume":"15","author":"A Brand","year":"1993","unstructured":"Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15(3\u20135):289\u201398.","journal-title":"Dev Neurosci"},{"issue":"10","key":"5879_CR80","first-page":"599","volume":"30","author":"S Thunell","year":"1992","unstructured":"Thunell S, Henrichson A, Floderus Y, Groth CG, Eriksson BG, Barkholt L, et\u00a0al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem. 1992;30(10):599\u2013606.","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"3","key":"5879_CR81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335\u20139.","journal-title":"Drugs"},{"issue":"6","key":"5879_CR82","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa1807838","volume":"380","author":"E Sardh","year":"2019","unstructured":"Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et\u00a0al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549\u201358.","journal-title":"N Engl J Med"},{"key":"5879_CR83","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2147\/DDDT.S281631","volume":"16","author":"CN Majeed","year":"2022","unstructured":"Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy. Drug Des Devel Ther. 2022;16:1827\u201345.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"5879_CR84","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.stemcr.2020.07.015","volume":"15","author":"F Prat","year":"2020","unstructured":"Prat F, Toutain J, Boutin J, Amintas S, Cullot G, Lalanne M, et\u00a0al. Mutation-specific guide RNA for compound heterozygous porphyria on-target scarless correction by CRISPR\/Cas9 in stem cells. Stem Cell Rep. 2020;15(3):677\u201393.","journal-title":"Stem Cell Rep"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-05879-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05879-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05879-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:45:58Z","timestamp":1772451958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-05879-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5879"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-05879-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the medical faculty, RWTH Aachen (reference no. EK 24-066). Consent to participate was given by the patient\u2019s parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AEM had financial support for a porphyria nurse by Alnylam pharmaceuticals (2022\u20132023) and unrestricted research grant by Clinuvel pharmaceuticals (2019\u20132021), both paid to the Stiftung f\u00fcr wissenschaftliche Forschung Stadtspital Z\u00fcrich. For the other authors, there are no financial and personal relationships with other people or organizations that could be viewed as inappropriate influence.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}